Zenith Epigenetics Appoints Julie Cherrington as President and CEO
Advertisement
Zenith Epigenetics Corp. announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization. Her accomplished employment record includes past notable positions such as CEO of Pathway Therapeutics Inc., President of Phenomix Corporation, Vice President, Preclinical Research and Exploratory Development SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences. Notably, Julie was a key contributor to the successful development of multiple FDA approved products including anti-virals and anti-cancer agent.
Donald J. McCaffrey , founding CEO, will assume the title of Chairman and Dr. Peter Johann will act as Lead Director.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.